Research progress in predictive biomarkers related to tumor immunotherapy / 国际肿瘤学杂志

ABSTRACT

Tumor immunotherapy is a treatment method mainly for programmed cell death-1 (PD-1) and its ligand PD-L1. PD-1/PD-L1 inhibitors have obvious clinical benefits and long-lasting responses in a variety of tumors. But overall response rates are still low. Studies show that PD-L1 and tumor mutation burden can predict the effect of immunotherapy. MSI-H/dMMR, TP53 and KRAS mutations are positively correlated with the effect of immunotherapy. While MDM2/4, EGFR, ALK and other genes are negatively correlated with the effect of immunotherapy.